First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

被引：0
|
作者：
Hossein Taghizadeh
Matthias Unseld
Andreas Schmiderer
Angela Djanani
Klaus Wilthoner
Dieter Buchinger
Gerald W. Prager
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Comprehensive Cancer Center,Clinical Division of Gastroenterology, Hepatology and Metabolism, Department of Internal Medicine I
[3] Medical University Innsbruck,Clinical Division of Oncology, Department of Medicine I
[4] Salzkammergut Klinikum,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Biliary tract cancer; Chemotherapy; Nanoliposomal irinotecan; Progression-free survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [1] First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
    Taghizadeh, Hossein
    Unseld, Matthias
    Schmiderer, Andreas
    Djanani, Angela
    Wilthoner, Klaus
    Buchinger, Dieter
    Prager, Gerald W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 109 - 115
  • [2] Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
    Allo, Gabriel
    Can, Ahu Damla
    Wahba, Roger
    Vogel, Nils
    Goeser, Tobias
    Kutting, Fabian
    Waldschmidt, Dirk
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (02)
  • [3] Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
    Rehman, Sana Saif Ur
    Lim, Kian
    Wang-Gillam, Andrea
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 485 - 492
  • [4] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    S Falk
    D Jackson
    British Journal of Cancer, 2002, 86 : 1677 - 1683
  • [5] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    Cunningham, D
    Falk, S
    Jackson, D
    BRITISH JOURNAL OF CANCER, 2002, 86 (11) : 1677 - 1683
  • [6] Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience
    Yu, Hung-Yuan
    Lee, Chun-Yang
    Lin, Le-Gin
    Chao, Yee
    Li, Chung-Pin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (01) : 42 - 50
  • [7] Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: Is this really a dangerous treatment?
    Idelevich, E
    Man, S
    Lavrenkov, K
    Gluzman, A
    Geffen, DB
    Shani, A
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (05) : 487 - 490
  • [8] Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
    Kawakami, Takeshi
    Todaka, Akiko
    Oshima, Kotoe
    Fushiki, Kunihiro
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Yokota, Tomoya
    Onozawa, Yusuke
    Yasui, Hirofumi
    Yamazaki, Kentaro
    BMC CANCER, 2023, 23 (01)
  • [9] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [10] Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens
    Moehler, M
    Hoffmann, T
    Hildner, K
    Siebler, J
    Galle, PR
    Heike, M
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2002, 40 (12): : 957 - 964
12345